Drugs / Fluorine F 18 Ara-G
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04186988 | Nov 2019 → Mar 2020 | non-small cell lung carcinoma | University of California, Davis | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT03007719 | Mar 2017 → Jan 2019 | urinary bladder cancer | Lawrence Fong | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluorine F 18 Ara-G | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03007719 ↗ |
| Modality | Diagnostic / imaging agent | “Diagnostic procedures, such as fluorine F 18 Ara-G PET/MR imaging” NCT03007719 ↗ |
| Route | Intravenous | “fluorine F 18 Ara-G intravenously (IV)” NCT03007719 ↗ |